Development of a Reversed Phase HPLC Method by Applying Scientific Approach and Strategies to Achieve Challenging Separation of Impurity Peaks in Typical Commercial Bulk Batches of Milbemycin Oxime (MO) Drug Substance.

Renuka P Rathnasekara, Milan K Dissanayake, Sarju Adhikari, Abu M Rustum
{"title":"Development of a Reversed Phase HPLC Method by Applying Scientific Approach and Strategies to Achieve Challenging Separation of Impurity Peaks in Typical Commercial Bulk Batches of Milbemycin Oxime (MO) Drug Substance.","authors":"Renuka P Rathnasekara, Milan K Dissanayake, Sarju Adhikari, Abu M Rustum","doi":"10.1093/jaoacint/qsaf034","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Typical commercial batches of milbemycin oxime (MO) contain over 25 related substances. Many of these related substance peaks exhibit similar chromatographic properties, often co-eluting or being poorly separated under current compendial methods. Therefore, an alternative HPLC method with greater selectivity and resolution for MO and its related substance peaks is highly desirable.</p><p><strong>Objective: </strong>This study aimed to develop and validate a new stability indicating HPLC method for adequately separating all peaks of interest in typical commercial batches of MO. Method: The final HPLC method utilizes a gradient elution on a HALO® C18 column (100 mm × 4.6 mm, I.D. 2.7 µm particle size) maintained at 50 °C, with a flow rate of 0.5 mL/min. The composition of mobile phase-A for the final method is water-acetonitrile-perchloric acid (70:30:0.06, v/v/v), and the composition of mobile phase-B is isopropanol-methanol-1,4 dioxane-perchloric acid (50:45:5:0.06, v/v/v/v). Injection volume of the new method is 6 µL and the detection wavelength is 240 nm.</p><p><strong>Results: </strong>The new HPLC method demonstrated specificity by adequately separating all potential MO-related substances in stress-degraded MO drug substance. It showed good linearity and accuracy in the range of 0.1% to 120% of the target MO analytical concentration. The limit of quantification and limit of detection were determined to be 0.1% and 0.03% of the analytical concentration, respectively. The robustness study found no critical parameters affecting the method's specificity or accuracy.</p><p><strong>Conclusions: </strong>The new HPLC method offers greater selectivity and resolution compared to compendial methods for the MO drug substance. It is more desirable for batch release and stability studies in both routine and non-routine activities.</p><p><strong>Highlights: </strong>An exhaustive equivalency study between the new HPLC method and the compendial methods demonstrated that the new method is superior compared to the European Pharmacopoeia (Ph. Eur.) method for analyzing MO bulk drug substance.</p>","PeriodicalId":94064,"journal":{"name":"Journal of AOAC International","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of AOAC International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jaoacint/qsaf034","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Typical commercial batches of milbemycin oxime (MO) contain over 25 related substances. Many of these related substance peaks exhibit similar chromatographic properties, often co-eluting or being poorly separated under current compendial methods. Therefore, an alternative HPLC method with greater selectivity and resolution for MO and its related substance peaks is highly desirable.

Objective: This study aimed to develop and validate a new stability indicating HPLC method for adequately separating all peaks of interest in typical commercial batches of MO. Method: The final HPLC method utilizes a gradient elution on a HALO® C18 column (100 mm × 4.6 mm, I.D. 2.7 µm particle size) maintained at 50 °C, with a flow rate of 0.5 mL/min. The composition of mobile phase-A for the final method is water-acetonitrile-perchloric acid (70:30:0.06, v/v/v), and the composition of mobile phase-B is isopropanol-methanol-1,4 dioxane-perchloric acid (50:45:5:0.06, v/v/v/v). Injection volume of the new method is 6 µL and the detection wavelength is 240 nm.

Results: The new HPLC method demonstrated specificity by adequately separating all potential MO-related substances in stress-degraded MO drug substance. It showed good linearity and accuracy in the range of 0.1% to 120% of the target MO analytical concentration. The limit of quantification and limit of detection were determined to be 0.1% and 0.03% of the analytical concentration, respectively. The robustness study found no critical parameters affecting the method's specificity or accuracy.

Conclusions: The new HPLC method offers greater selectivity and resolution compared to compendial methods for the MO drug substance. It is more desirable for batch release and stability studies in both routine and non-routine activities.

Highlights: An exhaustive equivalency study between the new HPLC method and the compendial methods demonstrated that the new method is superior compared to the European Pharmacopoeia (Ph. Eur.) method for analyzing MO bulk drug substance.

应用科学的方法和策略建立反相高效液相色谱法,以实现典型商业散装批次米尔霉素肟原料药杂质峰的分离。
背景:典型的商业批次米尔霉素肟(MO)含有超过25种相关物质。许多这些相关的物质峰表现出相似的色谱特性,通常是共洗脱或在目前的药典方法下很难分离。因此,需要一种选择性和分辨率更高的高效液相色谱方法来测定MO及其相关物质峰。目的:本研究旨在建立并验证一种新的稳定性指示高效液相色谱方法,以充分分离典型商业批MO中所有感兴趣的峰。方法:最终的高效液相色谱方法采用HALO®C18柱(100 mm × 4.6 mm,粒径2.7µm)梯度洗脱,保持在50°C,流速0.5 mL/min。最终方法的流动相a的组成为水-乙腈-高氯酸(70:30:0.06,v/v/v),流动相b的组成为异丙醇-甲醇-1,4二恶烷-高氯酸(50:45:5:0.06,v/v/v/v)。新方法进样量为6µL,检测波长为240 nm。结果:该方法特异性强,能充分分离出应激降解的MO原料药中所有潜在的MO相关物质。在目标MO分析浓度的0.1% ~ 120%范围内具有良好的线性和准确性。定量限和检测限分别为分析浓度的0.1%和0.03%。稳健性研究没有发现影响该方法特异性或准确性的关键参数。结论:与药典方法相比,该方法对MO原料药具有更高的选择性和分辨率。它更适合于常规和非常规活动的批释放和稳定性研究。重点:新方法与药典方法的详尽等效性研究表明,新方法优于欧洲药典(Ph. Eur.)分析MO原料药的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信